Drugs Disributed by Taro International Ltd
: Nucleoside & Guanosine Reverse Transcriptase Inhibitor. Lamivudine 300 mg, Abacavir 600 mg. TABS.:30. The recomm. dosage for adult.& child. over the age of 12 wt. at least 40 kg, is one tab., once dly. See lit.
Indicated in antiretrovir. comb. ther. for the tmt. of (HIV) infect. in adult., adolesc. and child. weigh. at least 25 kg.
C/I: Hypersens.
Retinoids. Adapalene 1 mg (0.1%), Benzoyl Peroxide 25 mg (2.5%). TOPICAL GEL: 30 g. For extern. use only. Thin layer of gel evenly over acne (pimples) affected areas should be appl. once dly., at bdtme. on a clean dry skin.
Eyes, lips, nostrils contact should be avoid. See lit.
Cutaneous tmt. of acne vulgaris when comedones, papules and pustules are present.
C/I: Hypersens.
Women who are preg. or suspect. to be preg.
Proteasome Inhibitor. Bortezomib 3.5 mg. VIAL (Pwdr. for sol. for inj.): 1×3.5 mg. Dosage should be ajust. individ. See lit.
Multiple Myeloma.
Mantle Cell Lymphoma: For the tmt. of pts/ with mantle cell lymphoma who have received at least one prior ther.
Bortezomib in comb. with rituximab, cyclophosphamide, doxorubicin & prednisone is indicated for the tmt. of adult pts. with previous. untreat. mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
C/I: Hypers. to bortezomib, boron or mannitol. Acute diffuse infiltrative pulmon. and pericard. dis. Intrathecal admin.
Endothelin Receptor Antagonist. Bosentan 62.5 mg, 125 mg. FC Tab 56 X 62.5/125 mg
Pulmonary arterial hypertension: In adult pts., initiate at a dose of 62.5 mg twice daily for 4 weeks and then incr. to maint. dose of 125 mg twice daily.
Systemic sclerosis with ongoing digital ulcer disease: initiate at a dose of 62.5 mg twice daily for 4 weeks and then incr. to maint. dose of 125 mg twice daily. Clinical experience is limited to 6 months.
The ptt’s response to tmt. and need for contin. ther. should be re-evaluated on a regular basis. A careful benefit / risk assessm. should be made, taking into consideration the liver tox. of bosentan. There are no data on the safety and efficacy in pts. under the age of 18 years.
Primary pulmonary arterial HT or second. to scleroderma or other connective tissue disease. To reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer dis.
C/I: Hypersens./ Moder. to sev. hepatic impairm. i.e. Child-Pugh Class B or C
/Baseline values of liver aminotransferases, i.e., aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT), greater than 3 times the upper limit of normal.
/ Concom. use of cyclosporine A
/ Pregn. Women of childbearing potent. who are not using reliable methods of contraception
NSAID. Bromfenac (as sodium sesquihydrate) 0.075% w/w. ophtalmic sol. 5ml. One drop appl. to the affect. eye twice daily (morn. and even.) 1 day prior to surg., the day of surg., and 14 days post-surg. To be admin. at least 5 min. after other topic. medic.
tmt. of postoper. inflam. and prevent. of ocular pain in adlt pts. undergoing cataract surg.
C/I:Hypersens.
Protein Kinase Inhibitor. Dasatinib 20, 50, 70, 80, 100, 140 mg. FC tabs:60 X 20,50,70 mg; 30X80,100,140 mg. Recomm. starting dose for chronic phase CML is 100 mg dasatinib dly.
Recomm. starting dose for acceler., myeloid or lymphoid blast phase (adv. phase) CML or Ph+ ALL is 140 mg once daily. See lit.
Newly diagn. Philadelphia chromos. posit. (Ph+) chron. myelogenous leuk. (CML) in the chron. phase. in adlts.
Chron., accel. or blast phase CML in adlts. with resist. or intoler. to prior ther. includ. imatinib mesilate.
Ph+ acute lymphoblastic leuk. (ALL) and lymphoid blast CML in adlts. with resist. or intol. to prior ther.
C/I:Hypersens.
